Literature DB >> 26583566

A model of acute kidney injury in mice with cirrhosis and infection.

Daniel E Carl1, Siddhartha S Ghosh1, Todd W B Gehr1, Antonio Abbate2, Stefano Toldo2, Arun J Sanyal3.   

Abstract

BACKGROUND & AIMS: Infectious acute kidney injury (AKI) is a life threatening complication of cirrhosis with limited therapeutic options. The aim of this study was to develop a model of infectious AKI in cirrhotic mice.
METHODS: Cirrhosis was established by intragastric administration of carbon tetrachloride (CCl4 ). Systemic haemodynamics was assessed invasively while cardiac function was assessed by echocardiography. AKI was induced using varying doses of lipopolysaccharide (LPS) titrated to produce 50% lethality. Renal function was assessed from serum creatinine and urine output (UOP). Renal injury was evaluated by urinalysis (proteinuria and casts) and renal histology. These mice were compared to: (i) normal mice, (ii) normal mice + LPS, and (iii) mice treated with CCl4 alone.
RESULTS: Cirrhosis with increased cardiac output, decreased systemic vascular resistance, activation of renin-angiotensin-aldosterone axis developed after 12 weeks of CCl4 administration. LPS injection produced a dose-dependent increase in mortality (33% at 2 mg/kg vs. 80% at 6 mg/kg) without urine (casts or proteinuria) or histological evidence of tubular injury. 2 mg/kg LPS injection produced a rise in creatinine (0.79 ± 0.27 mg/dl in CCl4 +LPS compared to 0.45 ± 0.14 in CCl4 alone, P < 0.05) and a decrease in UOP (0.86 ± 0.4 ml/16 h in CCl4 + LPS compared to 1.70 ± 0.7 ml/16 h in CCl4 mice, P < 0.05). UOP remained low in mice that died while it recovered over 48-72 h in those that recovered. Control mice treated with 2 mg/kg LPS did not experience AKI.
CONCLUSIONS: Cirrhotic CCl4 treated mice develop functional AKI and mimic most of the features of infectious AKI following LPS injection.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  acute kidney injury; animal models; cirrhosis; experimental models; hepatorenal syndrome; portal hypertension; splanchnic vasodilation; vasodilation and renal vasoconstriction

Mesh:

Substances:

Year:  2016        PMID: 26583566     DOI: 10.1111/liv.13023

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  5 in total

1.  Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice.

Authors:  Dae Joong Kang; Naga S Betrapally; Siddhartha A Ghosh; R Balfour Sartor; Phillip B Hylemon; Patrick M Gillevet; Arun J Sanyal; Douglas M Heuman; Daniel Carl; Huiping Zhou; Runping Liu; Xiang Wang; Jing Yang; Chunhua Jiao; Jeremy Herzog; H Robert Lippman; Masoumeh Sikaroodi; Robert R Brown; Jasmohan S Bajaj
Journal:  Hepatology       Date:  2016-07-29       Impact factor: 17.425

2.  Pioglitazone Ameliorates Acute Endotoxemia-Induced Acute on Chronic Renal Dysfunction in Cirrhotic Ascitic Rats.

Authors:  Szu-Yu Liu; Chia-Chang Huang; Shiang-Fen Huang; Tsai-Ling Liao; Nai-Rong Kuo; Ying-Ying Yang; Tzu-Hao Li; Chih-Wei Liu; Ming-Chih Hou; Han-Chieh Lin
Journal:  Cells       Date:  2021-11-05       Impact factor: 6.600

3.  Adaptive Mechanisms of Renal Bile Acid Transporters in a Rat Model of Carbon Tetrachloride-Induced Liver Cirrhosis.

Authors:  Chiara Donadei; Andrea Angeletti; Maria Cappuccilli; Massimiliano Conti; Diletta Conte; Fulvia Zappulo; Alessio De Giovanni; Deborah Malvi; Rita Aldini; Aldo Roda; Gaetano La Manna
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

4.  Recombinant Alkaline Phosphatase Prevents Acute on Chronic Liver Failure.

Authors:  Cornelius Engelmann; Danielle Adebayo; Marc Oria; Francesco De Chiara; Simone Novelli; Abeba Habtesion; Nathan Davies; Fausto Andreola; Rajiv Jalan
Journal:  Sci Rep       Date:  2020-01-15       Impact factor: 4.379

5.  The Lipopolysaccharide-Sensing Caspase(s)-4/11 Are Activated in Cirrhosis and Are Causally Associated With Progression to Multi-Organ Injury.

Authors:  Ugo Soffientini; Nigel Beaton; Sukriti Baweja; Emmanuel Weiss; Chhagan Bihari; Abeba Habtesion; Vishal Patel; Valerie Paradis; Archana Sharma; Tu Vinh Luong; Andrew Hall; Aida Nadar; Shiv Sarin; Shilpa Chokshi; Roger Williams; Benedicte Py; Richard Moreau; Rajiv Jalan; Gautam Mehta
Journal:  Front Cell Dev Biol       Date:  2021-07-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.